Skip to main content

Table 1 Demographic, clinical, radiological and follow-up of entire cohort and suspected or confimed COVID-19 cohort

From: Impact of COVID-19 pandemic in natural course of Moyamoya Angiopathy: an experience from tertiary-care-center in India

 

Entire cohort (n = 74)

Suspected or confirmed COVID-19 cohort (n = 14)

1. Mean age (years)

23.5 ± 16.1

17.6 ± 16.1

2. Pediatric MMA

52.7%

78.6%

3. Adult MMA

47.3%

21.4%

4. Male:Female

1:1.24

1:1

5. Area of residence

 Rural

64.9%

71.4%

 Urban

35.1%

28.6%

6. Duration of disease (months)

41.4 ± 31.5

36.3 ± 12.9

7. “MMA” type

 TIA

2.7%

7.1%

 Frequent TIA

16.2%

35.7%

 Cerebral infarction

62.2%

57.1%

 Intracerebral hemorrhage

8.1%

0%

 Headache

5.4%

0%

 Epilepsy

5.4%

0%

 Asymptomatic

0%

0%

 Others

0%

0%

8. Previously documented radiological lesion in brain

 Infarct

85.1%

78.6%

 Hemorrhage

6.8%

0%

 No acute lesion

8.1%

21.4%

9. Suzuki staging in the last documented in angiography

 Stage I

0%

0%

 Stage II

9.5%

7.1%

 Stage III

29.7%

28.6%

 Stage IV

37.8%

50.0%

 Stage V

21.6%

14.2%

 Stage VI

1.4%

0%

10. Time since last follow-up (months)

9.2 ± 1.7

9.6 ± 1.6

11. Compliance to prescribed medications

 Yes

90.5%

92.9%

 No

9.5%

7.1%

12. Neurological symptoms (worsening or new onset)

 Yes

16.2%

64.3%

 No

83.8%

35.7%

  1. n: Number; MMA: Moyamoya angiopathy; TIA: Transient ischemic attack